S-ADENOSYLMETHIONINE IN THE TREATMENT OF EXPERIMENTAL HEPATIC ENCEPHALOPATHY
Abstract
Background. Hepatic encephalopathy (HE) is the most severe complication of both acute and chronic liver failure.
Current pharmacotherapy options for HE being limited, it necessitates the search for alternative treatments of this pathology.
Objective – to evaluate the efficacy of S-adenosylmethionine (SAM) in treatment of experimental HE in rats.
Materials and methods. The domestic drug HeptalNAN (Akadempharm, Belarus) has been used as a source of SAM. Rats with thioacetamide-induced HE (350 mg/kg, intraperitoneally, during 3 days) were used in the experiment. SAM in two doses (200 and 400 mg/kg) was administered 4 times via gastric tube. Behavioral tests, biochemical and histological methods were used to evaluate SAM pharmacological effects.
Results. The administration of SAM improved behavioral reactions of animals with HE, decreased the serum concentrations of ammonia and nitrogenous wastes, demonstrated hepatoprotective and antioxidant effects. A low dose of SAM (200 mg/kg) reduced rat mortality and decreased serum concentration of TNF-α.
Conclusion. SAM showed protective effect in experimental HE by improving behavioral reactions, decreasing blood ammonia concentration and having hepatoprotective and antioxidant effects.
References
1. Toris GT, Bikis CN, Tsourouflis GS, Theocharis SE. Hepatic encephalopathy: an updated approach from pathogenesis to treatment. Medical Science Monitor. 2011;17(2):RA53-63. doi:10.12659/msm.881387.
2. Chen SJ, Wang LJ, Zhu Q, Cai JT, Chen T, Si JM. Effect of H pylori infection and its eradication on hyperammonemia and hepatic encephalopathy in cirrhotic. World Journal of Gastroenterology. 2008;14(12):1914-1918. doi:10.3748/wjg.14.1914.
3. Nencki M, Pawlow I, Zaleski J. Über den ammoniakgehalt des blutes under der organe und die harnstoffbildung bei den saugethieren. Archiv für experimentelle Pathologie und Pharmakologie. 1896;37(1):26-51. (German).
4. 4. Shawcross DL, Olde Damink SW, Butterworth RF, Jalan R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metabolic Brain Disease. 2005;20(3):169-179. doi: 10.1007/s11011-005-7205-0.
5. Jawaro T, Yang A, Dixit D, Bridgeman MB. Management of hepatic encephalopathy: A primer. Annals of Pharmacotherapy. 2016;50(7):569-577. doi: 10.1177/1060028016645826.
6. Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for hepatic encephalopathy. Drugs. 2010;70(9):1131-1148. doi: 10.2165/10898630-000000000-00000.
7. Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. International Journal of Research in Medical Sciences. 2019;7(6):2482-2493. doi: 10.18203/2320-6012.ijrms20192550.
8. Fischer JE, Yoshimura N, Aguirre A, James JH, Cummings MG, Abel RM, Deindoerfer F. Plasma amino acids in patients with hepatic encephalopathy. American Journal of Surgery. 1974;127(1):40-47. doi:10.1016/0002-9610(74)90009-9.
9. Lee SY, Ko KS. Protective effects of S-adenosylmethionine and its combinations with taurine and/or betaine against lipopolysaccharide or polyinosinic-polycytidylic acid-induced acute hepatotoxicity. Journal of Cancer Prevention. 2016;21(3):152-163. https://doi.org/10.15430/JCP.2016.21.3.152.
10. Schmid RD, Hovda LR. Acute hepatic failure in a dog after xylitol ingestion. Journal of Medical Toxicology. 2016;12(2):201-205. doi:10.1007/s13181-015-0531-7.
11. Song Z, Zhou Z, Chen T, Hill D, Kang J, Barve S, McClain C. S-adenosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicity in mice. Journal of Nutritional Biochemistry. 2003;14(10):591-597. doi:10.1016/s0955-2863(03)00116-5.
12. De Caprio M, Carbone G, Cerotto GM, Corbosiero L, Vitale A. Behavior of ammonemia during treatment of chronic/hyperammonemic hepatopathy with S-adenosyl-Lmethionine. Clinical Therapeutics. 1980;92(6):587-602.
13. Ferrigno A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M. Liver plays a central role in asymmetric dimethylargininemediated organ injury. World Journal of Gastroenterology. 2015;21(17):5131-5137. doi:10.3748/wjg.v21. i17.5131.
14. Czarnecka A, Milewski K, Jaźwiec R, Zielińska M. Intracerebral administration of S-adenosylhomocysteine or S-adenosylmethionine attenuates the increases in the cortical extracellular levels of dimethylarginines without affecting cGMP. Neurotoxicity Research. 2017;31(1):99-108. doi:10.1007/s12640-016-9668-7.
15. Butterworth RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, Blei AT; Members of the ISHEN Commission on Experimental Models of HE. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver International. 2009;9(6):783-788. doi: 10.1111/j.1478-3231.2009.02034.x.
16. Farjam M, Dehdab P, Abbassnia F, Mehrabani D, Tanideh N, Pakbaz S, Imanieh MH. Thioacetamide-induced acute hepatic encephalopathy in rat: behavioral, biochemical and histological changes. Iranian Red Crescent Medical Journal. 2012;14(3):164-170.
17. Akerboom TP, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfide in biological samples. Methods in Enzymology. 1981;77:373-382. doi: 10.1016/s0076-6879(81)77050-2.
18. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods in Enzymology. 1978;52:302-310. https://doi.org/10.1016/S0076-6879(78)52032-6.
1.png)
